Osimertinib, a third-generation and irreversible mutant-selective EGFR-TKI, has been approved for advanced NSCLC patients harboring EGFR mutations, including the T790M mutation, based on the results of the AURA3 trial [8]. Here, EGFR is linked to non-small cell lung carcinoma.